Alpha 2.0
Login Register
» Articles » PMID: 4076233

Immunoreactivity of Monoclonal Anti-melanoma Antibodies in Relation to the Amount of Radioactive Iodine Substituted to the Antibody Molecule

Overview
Journal Eur J Nucl Med
Specialty Nuclear Medicine
Date 1985 Jan 1
PMID 4076233
Citations 9
Authors
S Matzku
H Kirchgessner
W G Dippold
J Bruggen
Affiliations
Soon will be listed here.
Abstract

The damage to monoclonal anti-melanoma antibodies caused by iodination was investigated by comparing the results obtained using the chloramine-T method and the 1,3,4,6-tetrachloro-3 alpha, 6 alpha-diphenyl-glycoluril (IODOGEN) method at different levels of iodine substitution to the molecule. The level of substitution at which losses in immunoreactivity occurred was evaluated in each monoclonal antibody (MAb) studied. This phenomenon was not dependent on the method of substitution, provided that mild conditions of reaction were used. Lineweaver-Burk plots and--in cases of alterations in binding affinity--Scatchard plots were found to provide an adequate description of the binding behaviour of individual MAbs after labelling. Immunoreactivity was shown to be determined not only by the proportion of bona fide reactive MAb molecules, but also by a substitution-dependent decrease in affinity constants. The practical consequences of altered binding parameters were demonstrated by quantitating specific antibody accumulation in melanoma transplants in vivo.

Citing Articles

Factors affecting the antigen-antibody reaction.

Reverberi R, Reverberi L Blood Transfus. 2009; 5(4):227-40.

PMID: 19204779 PMC: 2581910. DOI: 10.2450/2007.0047-07.

Criteria for selecting monoclonal antibodies with respect to accumulation in melanoma tissue.

Matzku S, Bruggen J, Brocker E, Sorg C Cancer Immunol Immunother. 1987; 24(2):151-7.

PMID: 3829049 PMC: 11038094. DOI: 10.1007/BF00205593.

Labeling of monoclonal antibodies with a 67Ga-phenolic aminocarboxylic acid chelate. Part II. Comparison of immunoreactivity and biodistribution of monoclonal antibodies labeled with the 67Ga-chelate or with 131I.

Matzku S, Schuhmacher J, Kirchgessner H, Bruggen J Eur J Nucl Med. 1986; 12(8):405-12.

PMID: 3792375 DOI: 10.1007/BF00252199.

Comparative tumour localization properties of radiolabelled monoclonal antibody preparations of defined immunoreactivities.

Pimm M, Baldwin R Eur J Nucl Med. 1987; 13(7):348-52.

PMID: 3428284 DOI: 10.1007/BF00252993.

Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody.

Mantovani L, Menard S, Mezzanzanica D, Miotti S, Pupa S, Colnaghi M Br J Cancer Suppl. 1990; 10:15-7.

PMID: 2383475 PMC: 2149501.

References
1.
Ey P, Prowse S, JENKIN C . Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry. 1978; 15(7):429-36. DOI: 10.1016/0161-5890(78)90070-6. View
2.
Dippold W, Knuth A, Meyer zum Buschenfelde K . Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res. 1984; 44(2):806-10. View
3.
Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View
4.
Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn Jr P . Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984; 72(1):77-89. DOI: 10.1016/0022-1759(84)90435-6. View
5.
Suter L, Brocker E, Bruggen J, Ruiter D, Sorg C . Heterogeneity of primary and metastatic human malignant melanoma as detected with monoclonal antibodies in cryostat sections of biopsies. Cancer Immunol Immunother. 1983; 16(1):53-8. PMC: 11039163. DOI: 10.1007/BF00199906. View